Essex Woodlands backs Chinese healthcare growth with new Shanghai office


Healthcare-focused growth capital firm Essex Woodlands has announced a new office in China to help it focus on the country’s medical sector amid rapid middle-class growth.

The firm already has experience in the country through its investments in China Cord Blood and artery tube manufacturer Microport Scientific.

Essex said the office will lead its investments in China, which will focus on pharmaceuticals, medical technology and IT amid middle class expansion, increased government healthcare funding and an accelerating rate of chronic disease.

The new office will be co-run by managing directors Scott Barry and David Yang, pictured.

Barry has been a partner in the firm’s New York office for six years covering speciality pharmaceuticals, biotechnology, medical device and healthcare services investments.

Yang, who only joined Essex in April, has more than 10 years of experience in healthcare private equity and investment banking in China and the US, and was previously an executive director with Warburg Pincus’ China healthcare team.

He said, “China is an important geography for Essex Woodlands.

“Private equity investments in healthcare in China are increasing steadily, healthcare mergers and acquisitions are increasing, and healthcare IPOs are raising more capital in China than in the US today.”

Barry added, “The opening of an office in Shanghai is a strategic decision to increase our growth and presence in this region.

“We will now have the presence, scale, and infrastructure in China to partner with and invest in local companies to help them develop high quality healthcare products and services.”

Copyright © 2012 AltAssets